Alternate Biomarker Necessary for HER2 Breast Cancer Prognoses

Alternate Biomarker Necessary for HER2 Breast Cancer Prognoses
shutterstock_203004220Despite the utility of certain biomarkers in predicting triple negative breast cancer outcomes after chemotherapy treatment, it appears as though the level of tumor-infiltrating lymphocytes (S-TILs) cannot predict the outcome when trastuzumab, an antibody targeted against HER2 protein, is used. These results, produced by the laboratory of Edith A. Perez, MD, at the Mayo Clinic Cancer Center, are insightful to clinicians who want to choose the correct therapy for their breast cancer patients. "This study is part of a series we are conducting to determine which patients should use trastuzumab," stated Dr. Perez in a news release from the Mayo Clinic. "We are now giving it to everyone whose tumors are HER2-positive, but not every patient benefits." As is true for any drug that can have adverse side effects, it is best not to treat patients with trastuzumab if there are no positive effects. Yet these findings are far from dismal. Although S-TILs do not
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.